One of the first things I explain to leaders arriving in the Gulf from other markets: you don't set the public price. The health authority does. And between your warehouse and the patient stand a distributor, insurers, committees and tenders, each with its own rules.
A country manager can build a strong brand and a strong team and still watch patients fail to get the product. Access decides how much of your work ever reaches them. Step 4 of the Pharma Career Ladder for country managers is distributors and market access.
Choose and run the distributor
Choosing a distributor is one of the longest decisions you make, and easy to make on the first good offer or a familiar name. I ask 5 questions. What's their real reach, from their own data? Do they have the licences, cold chain, tender experience and a clean compliance record? How many competing brands do they carry? Will they share sell-out and stock by customer every month? And who owns the customer? The distributor handles supply, invoicing and collection. The relationship with doctors stays with your team, and scientific questions go to medical affairs. Before any shortlist is final, walk their warehouse.
Managing a distributor means reading 4 numbers together every month: sell-out by channel, stock cover in months of sell-out, service level, and the actions both sides agreed last month. When stock cover rises, sell-in should wait. Meet the general manager monthly, agree the annual plan together, and keep every term in the contract. If you only meet your distributor in a crisis, every meeting will be one.
Know who decides and who pays
Many launch plans start and end with the doctor. In many Gulf markets the doctor chooses the medicine and someone else decides who pays for it. Understanding the payer means mapping them for each brand: the health authority, insurers, claims administrators, formulary committees, the prescriber and the patient. Each asks a different question, and none of them wants a relationship instead of evidence.
Pricing and reimbursement basics follow a sequence. Register the product. Submit the price dossier, and the authority sets the public price. Build the value case for insurers and committees. Secure listing and cover, one payer at a time. A registered price isn't yet a covered medicine, so never build a forecast as if cover arrives the day after registration.
That's the regulatory reality behind every launch date. Dossier readiness, how fully you answer authority queries, price approval, and listing and first stock all decide it. Plan the launch from the regulatory timeline, review the tracker monthly with regulatory, medical, supply and marketing, and tell headquarters early when a date moves.
Working with health authorities builds credibility before you need it. Learn each department's process and follow it. Send complete files, use formal channels, answer every query fully, and raise safety and supply risks early. Share expertise when invited, with nothing offered in return. Credibility with an authority is built in the years you need nothing.
Win tenders and stay listed
Winning a tender rarely goes wrong on the day. It goes wrong earlier: a lapsed certificate, a bid price nobody approved, stock you can't confirm. Know the tender calendar, keep the file complete, approve the price and plan supply in advance, and bid exactly to the rules through the official channel only. Winning a tender you can't supply is worse than losing it. Review every result with the team.
With guidelines and formularies, the listing is closer to the start than the finish. Know each committee, submit complete evidence through the hospital's official route, supply without gaps, and update the file when guidelines change. A listing rarely goes in one meeting. It fades. Getting listed is an event. Staying listed is a habit.
That's one reason hospital versus retail strategy needs 2 plans. Hospitals run on committees, tenders and key account managers who work with many stakeholders. Retail runs on availability, pharmacist trust and reps with wide coverage. One rep with one message sent into both usually does neither well.
Keep every engagement clean
Patient support programmes start from a real patient need, are designed by medical and compliance, and have no link to prescribing. Patient data stays with the programme, and every adverse event is reported. Ask: would it still make sense if it sold nothing?
Building a KOL plan means mapping influence from publications, guideline panels and teaching roles. A KOL is someone other doctors follow. Paid roles exist only for a documented need, at fair market value, and no engagement is ever linked to prescribing.
The advisory board worth holding starts with a question you can write down. Choose experts for the question, pay fair market value under a written contract, and act on the written advice. Medical leads it and compliance approves it.
All of this is why compliance is a commercial asset. The shortcut brings investigations and lost trust. The strict way earns the trust of doctors, authorities and good people. Bring compliance in at the start. The team watches what you allow far more than what you say.
Read the market before you act
Market research worth paying for has a decision attached. Before approving any study, write down what you'll do with each possible answer. If every answer leads to the same action, skip it. Research interviews with doctors stay research, never a sales call.
Reading a market before entering takes 4 questions: size in treated patients, growth and its driver, competition seen through Porter's five forces, and access. Access is the one the slide leaves out. Write down in advance what would make you wait.
Parallel import and leakage starts at home. Did you ship more than the market needed? Is the forecast built on real demand? Are distributor agreements clear, lawful and reviewed by legal? A lawful order is supplied. Watch sell-out and distributor inventory side by side, because the drift between them is the earliest signal.
When the answer is no
Every country leader eventually gets the letter: not listed, or reimbursement refused. When access fails, ask formally what the committee found missing. Rebuild the case with medical, and resubmit only when something has truly changed. Move effort to where the product is listed, and reset the forecast openly with the team and headquarters. Never blame the committee. The same people review the next submission. A refusal is feedback on the case, not a verdict on the brand.
Your checklist for this week
- Ask your distributor for sell-out and stock by customer, and set a monthly meeting with their general manager
- Map every payer for your next launch brand
- Rebuild your next launch date from the regulatory tracker
- List the tenders for the next 12 months and check each file is complete
- Check every advisory board and KOL engagement has a written, documented need
- Put sell-out and distributor inventory side by side for each key brand
- Pick 1 listing at risk and plan supply and follow-up for it
That's Step 4. Next week Step 5 begins: building the organisation.